文献速递临床试验与 GCP

非诺贝特类药物治疗胆汁淤积性瘙痒(FITCH):随机对照试验研究方案

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-05-23

FITCH是一项多中心、研究者发起的双盲随机安慰剂对照试验,计划纳入84例伴有瘙痒的原发性胆汁管炎或原发性/继发性硬化性胆管炎成人患者,评估贝扎贝特400 mg每日四次治疗21天后瘙痒强度(视觉模拟量表)降低50%及以上的患者比例。次要结局包括五维瘙痒评分、肝病特异性生活质量、血清肝功和自分泌运动因子活性,并评估肾功能、横纹肌溶解相关血清指标及不良事件。

要点

  • FITCH为多中心、研究者发起的双盲随机安慰剂对照试验,计划纳入84例成人胆汁淤积性肝病伴瘙痒患者。
  • 主要结局为贝扎贝特400 mg每日四次或安慰剂治疗21天后视觉模拟量表瘙痒强度降低50%及以上的患者比例。
  • 安全性通过肾功能和横纹肌溶解相关血清参数及(严重)不良事件的精确记录进行评估。

核心结论

  • 鉴于贝扎贝特良好的安全性特征和抗胆汁淤积特性,贝扎贝特可能成为治疗胆汁淤积性瘙痒的新一线治疗选择。

研究设计与样本

  • 多中心、研究者发起的双盲随机安慰剂对照试验,计划纳入84例原发性胆汁管炎或原发性/继发性硬化性胆管炎成人患者。
  • 干预为贝扎贝特400 mg每日四次或安慰剂治疗21天。

主要发现

  • 主要结局为治疗21天后视觉模拟量表瘙痒强度降低50%及以上的患者比例。
  • 次要结局包括贝扎贝特对五维瘙痒评分、肝病特异性生活质量、血清肝功和自分泌运动因子活性的影响。
  • 安全性通过肾功能和横纹肌溶解相关血清参数及(严重)不良事件的精确记录进行评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pruritus (itch) is a frequent, burdensome and difficult-to-treat symptom in patients with cholestasis. Fibrates are currently under investigation for the treatment of primary biliary cholangitis in patients with a suboptimal response to ursodeoxycholic acid. Moreover, there is empirical evidence for a possible antipruritic effect. We aim to prove this in a randomized controlled trial, including patients with cholestatic liver diseases other than primary biliary cholangitis that are accompanied by pruritus. METHODS: A multicenter investigator-initiated, double-blind, randomized placebo-controlled trial to evaluate the effect of bezafibrate on cholestatic pruritus in 84 adult patients with primary biliary cholangitis or primary/secondary sclerosing cholangitis. Primary outcome is the proportion of patients with a reduction of itch intensity of 50% or more (measured on a Visual Analog Scale) after 21 days of treatment with bezafibrate 400 mg qid or placebo. Secondary outcomes include the effect of bezafibrate on a five-dimensional itch score, liver disease-specific quality of life, serum liver tests and autotaxin activity. Safety will be evaluated through serum parameters for kidney function and rhabdomyolysis as well as precise recording of (serious) adverse events. We provide a schematic overview of the study protocol and describe the methods used to recruit and randomize patients, collect and handle data and perform statistical analyses. DISCUSSION: Given its favorable safety profile and anticholestatic properties, bezafibrate may become the new first-line treatment option for treating cholestatic pruritus. TRIAL REGISTRATION: Netherlands Trial Register, ID: NCT02701166 . Registered on 2 March 2016; Netherlands Trial Register, ID: NTR5436 . Registered on 3 August 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bolier R, de Vries ES, Parés A, et al. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28535810. doi:10.1186/s13063-017-1966-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。